Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757392 · ClinicalTrials.gov registry record · Phase 2
Candin Safety & Efficacy Study for the Treatment of Warts
A Phase 2 study of Human Papilloma Virus and Warts, sponsored by Nielsen BioSciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01757392: Completed Phase 2 study of Human Papilloma Virus and Warts, sponsored by Nielsen BioSciences.
NCT01757392 is a Phase 2 study of Human Papilloma Virus and Warts that has completed, run by Nielsen BioSciences. The registered enrollment target is 39 participants, below the 8,440-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01757392, a Phase 2 study of Human Papilloma Virus and Warts, has completed, sponsored by Nielsen BioSciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
Conditions Studied
Interventions
- BIOLOGICAL Candida albicans Skin Test Antigen
Study Locations (1)
Arkansas
- Johnson Dermatology - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT01757392 record still lists
NCT01757392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 8,440-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Candida albicans Skin Test Antigen is the first listed.
NCT01757392 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT01757392 about?
NCT01757392 is a clinical study titled "Candin Safety & Efficacy Study for the Treatment of Warts". The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
What is the current status of trial NCT01757392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2012-09. Estimated completion is 2014-12.
What conditions does trial NCT01757392 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Warts.
What interventions are being tested in trial NCT01757392?
The interventions under investigation include: Candida albicans Skin Test Antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01757392?
This trial is sponsored by Nielsen BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01757392 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01757392's enrollment target sits among peer trials
39 31st of 39 higher than 9 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
RECRUITING · Phase 2
-
De-Escalation Therapy for Human Papillomavirus Negative Disease
COMPLETED · Phase 2
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
-
Study of Gardasil in Mid-Adult Males (MAM)
COMPLETED · Phase 2
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia